Zacks Investment Research
09 Sept 2026, 22:50 UTC · 1d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
UnitedHealth Group (UNH) is currently assigned a Zacks Rank #1 (Strong Buy). — A top-tier analyst rating from a recognized research firm typically serves as a positive catalyst for investor sentiment and buying pressure.
+0.60UnitedHealth Group's upcoming quarterly EPS is forecasted to increase by 38.01% year-over-year to $4.03. — Significant projected earnings growth is a primary driver of stock price appreciation.
+0.50UNH is trading at a Forward P/E ratio of 20.23, which is a discount relative to its industry average of 23.33. — Relative undervaluation suggests a margin of safety and potential for price correction upward to meet industry norms.
+0.30Continue reading
5 related stories
Search tags
The Zacks Consensus EPS estimate for UNH has moved 0.57% higher within the past month. — Positive revisions in analyst estimates generally correlate with near-term stock price increases.
Expected quarterly revenue for UnitedHealth Group is $111.38 billion, representing a 1.57% decrease from the prior year. — Slightly declining revenue indicates a potential slowdown in top-line growth despite earnings increases.
-0.20Which stocks this story touches
The company is rated as a Zacks Rank #1 (Strong Buy) with positive EPS growth forecasts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
9h ago
